With Phase 1 testing now complete and showing positive results, Ben Franklin client US Specialty Formulations, Allentown, is moving forward with its oral COVID-19 vaccine. The company is partnering with Ben Franklin client and TechVentures resident VaxForm, Bethlehem, to bring a vaccine to market that company leaders believe will be easier to tolerate and more effective than the current injection vaccines on the market.
Phase I testing shows that the oral vaccine seems to perform better than some of the platforms that are already on the market. It fights all three major variants of COVID-19, and it is hoped to be able to fight all variants of the virus. It is also easier to tolerate by patients than the injectable vaccines currently on the market. Its shelf stability and ease of administration make it easier to transport, store, and administer both nationally and internationally.
The company hopes to receive Emergency Use Authorization to begin distribution of the vaccine this Fall, while the second and third phase trials are underway. Via Lehigh Valley Business